1877 Stock Overview
A biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Shanghai Junshi Biosciences Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$15.14 |
| 52 Week High | HK$21.70 |
| 52 Week Low | HK$9.17 |
| Beta | 0.74 |
| 1 Month Change | 4.56% |
| 3 Month Change | 41.76% |
| 1 Year Change | 55.92% |
| 3 Year Change | -72.04% |
| 5 Year Change | -55.47% |
| Change since IPO | -36.25% |
Recent News & Updates
Recent updates
Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Surges 37% Yet Its Low P/S Is No Reason For Excitement
Mar 03
Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Price Is Right But Growth Is Lacking After Shares Rocket 35%
Oct 14Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?
Sep 30Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Revenues Are Not Doing Enough For Some Investors
Aug 29Shanghai Junshi Biosciences (HKG:1877) Has Debt But No Earnings; Should You Worry?
Jun 28Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Fly 27% But Investors Aren't Buying For Growth
May 06Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?
Mar 22Risks Still Elevated At These Prices As Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Dive 29%
Jan 26Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?
Dec 17Is Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Trading At A 38% Discount?
Nov 20Health Check: How Prudently Does Shanghai Junshi Biosciences (HKG:1877) Use Debt?
Sep 05Revenues Not Telling The Story For Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)
May 22Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Could Be 35% Below Their Intrinsic Value Estimate
May 01Shareholder Returns
| 1877 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 14.7% | 22.1% | 8.2% |
| 1Y | 55.9% | 52.8% | 18.5% |
Return vs Industry: 1877 exceeded the Hong Kong Biotechs industry which returned 52.8% over the past year.
Return vs Market: 1877 exceeded the Hong Kong Market which returned 18.5% over the past year.
Price Volatility
| 1877 volatility | |
|---|---|
| 1877 Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 13.3% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in HK Market | 15.1% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 1877's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1877's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 2,532 | Cong Li | www.junshipharma.com |
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Shanghai Junshi Biosciences Co., Ltd. Fundamentals Summary
| 1877 fundamental statistics | |
|---|---|
| Market cap | HK$27.65b |
| Earnings (TTM) | -HK$1.36b |
| Revenue (TTM) | HK$2.07b |
7.2x
P/S Ratio-11.0x
P/E RatioIs 1877 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1877 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.95b |
| Cost of Revenue | CN¥410.68m |
| Gross Profit | CN¥1.54b |
| Other Expenses | CN¥2.82b |
| Earnings | -CN¥1.28b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 25, 2025
| Earnings per share (EPS) | -1.30 |
| Gross Margin | 78.92% |
| Net Profit Margin | -65.75% |
| Debt/Equity Ratio | 49.0% |
How did 1877 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/15 01:23 |
| End of Day Share Price | 2025/04/15 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shanghai Junshi Biosciences Co., Ltd. is covered by 13 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Congmin Yuan | Citic Securities Co., Ltd. |
| Wangbin Zhou | Citigroup Inc |
| null null | Credit Suisse |